Collectively, we uncovered a completely new facet of ODAD2 function by identifying it as a novel NF-κB negative regulator, thus uncovering ODAD2 as a potential new therapeutic target in CRC [44]. This evidence concerns the gene NFKB1 and colorectal carcinoma.